Literature DB >> 11526327

Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody.

S Covaceuszach1, A Cattaneo, D Lamba.   

Abstract

The monoclonal antibody MNAC13 is a potent antagonist that prevents the binding of nerve-growth factor (NGF) to its tyrosine kinase A receptor (TrkA) in a variety of systems. Structural studies of the FabMNAC13 fragment were performed to gain insights into the mechanism of action of this potentially therapeutic monoclonal antibody. The optimal conditions for crystallization of FabMNAC13 were determined. Crystals appeared as prismatic bundles, displayed P2(1)2(1)2(1) space-group symmetry and diffracted to a resolution of 1.8 A. The unit-cell parameters were determined to be a = 52.73, b = 67.55, c = 111.43 A. The data set was 99.5% complete. Molecular replacement was performed, resulting in a correlation coefficient of 0.55 and an R value of 0.40. The structure refinement is now in progress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526327     DOI: 10.1107/s0907444901010666

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  3 in total

1.  The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.

Authors:  Gabriele Ugolini; Sara Marinelli; Sonia Covaceuszach; Antonino Cattaneo; Flaminia Pavone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

Review 2.  The evolution of nerve growth factor inhibition in clinical medicine.

Authors:  Barton L Wise; Matthias F Seidel; Nancy E Lane
Journal:  Nat Rev Rheumatol       Date:  2020-11-20       Impact factor: 20.543

3.  Nerve growth factor favours long-term depression over long-term potentiation in layer II-III neurones of rat visual cortex.

Authors:  Alfredo Brancucci; Nicola Kuczewski; Sonia Covaceuszach; Antonino Cattaneo; Luciano Domenici
Journal:  J Physiol       Date:  2004-07-08       Impact factor: 5.182

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.